

Covalon Granted Key Antimicrobial Patents in the United States, Canada, and Europe

MISSISSAUGA, Ontario – June 3rd, 2020 – /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that the Company has been granted key antimicrobial patents by the United States Patent and Trademark Office ("USPTO"), the Canadian Intellectual Property Office ("CIPO"), and the European Patent Office ("EPO").

Covalon's Antimicrobial Silicone-based Wound Dressing patent has been granted in the United States by the USPTO, in Canada by the CIPO, and in Europe by the EPO. This antimicrobial patent is integral to the Company's CovaClear® platform technology and the Company's IV Clear®, MediClear® PreOp, and SurgiClear® products.

The USPTO also granted the Company a patent for a Method for the Reduction of Microbial Skin Flora, which protects the Company's novel product MediClear PreOp. MediClear PreOp is indicated for use as a pre-operative drape that provides continuous antimicrobial activity to reduce the risk of contamination of the skin prior to a surgical procedure.

"This is a major accomplishment to protect the only dual-antimicrobial silicone adhesive technology on the market," said Brian Pedlar, Covalon's Chief Executive Officer. "We are very pleased to see that the United States, Canadian, and European patent offices have all recognized Covalon's innovations in antimicrobial technologies through the granting of these patents. Protecting patients from infection during hospital procedures is a significant growth opportunity and these patents solidify Covalon's advantage in this market."

IV Clear® is the only dual-antimicrobial fully transparent silicone vascular access dressing on the market. The patented technology incorporates chlorohexidine and silver into the entire surface area of the adhesive, ensuring the greatest area of coverage and protection from bacterial migration by preventing regrowth of microorganisms most commonly associated with CRBSI's (catheter-related bloodstream infections) for up to seven days.

MediClear PreOp® is a novel self-adherent dual-antimicrobial film indicated for use as a pre-operative drape that kills, on average, 99.99% of microorganisms in just 30 minutes, while also physically isolating the site from external contaminants, ensuring complete site protection leading up to surgery. MediClear PreOp is designed to be applied by the patient or a clinician prior to a surgical procedure and removed in the operating room just before surgery.

SurgiClear® is a post-surgical dressing designed to protect patients during recovery. This dual-antimicrobial dressing is applied over a closed surgical wound to provide barrier protection to external contaminants, full visibility of the healing site, and full-surface antimicrobial coverage to protect the patient from bacterial regrowth for up to seven days. The soft silicone technology conforms extremely well to the contours of the skin, allowing for better mobility during recovery without sacrificing antimicrobial protection.

To learn more about Covalon, please contact:

Brian Pedlar, CEO, Covalon Technologies Ltd.
Email: bpedlar@covalon.com
Phone: 905.568.8400 x 233
Toll free: 1.877.711.6055
Web site: www.covalon.com
Twitter: @covalon

About Covalon

Covalon Technologies Ltd. researches, develops, and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products, and services address the advanced healthcare needs of medical device companies, healthcare providers, and individual consumers. Covalon's technologies are used to prevent, detect, and manage medical conditions in specialty areas such as infection control, vascular access, surgical procedures, advanced wound care, and medical device coatings. To learn more about Covalon, visit our website at www.covalon.com.

IV Clear®, MediClear®, and SurgiClear® are registered trademarks of Covalon Technologies Ltd. in Canada, the United States and the United Kingdom.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release may constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "proposed" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current believe or assumptions as to the outcome and timing of such future events. Such forward-looking information is subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements. Various assumptions or factors are typically applied in drawing conclusions or making the forecast or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Source: Covalon Technologies Ltd.

- 30 -